Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.
2.

Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.

Sauerborn M, van Dongen W.

BioDrugs. 2014 Aug;28(4):383-91. doi: 10.1007/s40259-014-0096-z. Review.

PMID:
24842227
3.

Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin.

Torosantucci R, Brinks V, Kijanka G, Halim LA, Sauerborn M, Schellekens H, Jiskoot W.

J Pharm Sci. 2014 May;103(5):1367-74. doi: 10.1002/jps.23935. Epub 2014 Mar 11.

PMID:
24619587
4.

Is the tiered immunogenicity testing of biologics the adequate approach in preclinical development?

Sauerborn M.

Bioanalysis. 2013 Apr;5(7):743-6. doi: 10.4155/bio.13.43. No abstract available.

5.

Antibody response against Betaferon® in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory.

Sauerborn M, van Beers MM, Jiskoot W, Kijanka GM, Boon L, Schellekens H, Brinks V.

J Clin Immunol. 2013 Jan;33(1):255-63. doi: 10.1007/s10875-012-9783-z. Epub 2012 Sep 4.

PMID:
22945588
6.

Natural antibodies against bone morphogenic proteins and interferons in healthy donors and in patients with infections linked to type-1 cytokine responses.

Sauerborn M, van de Vosse E, Delawi D, van Dissel JT, Brinks V, Schellekens H.

J Interferon Cytokine Res. 2011 Sep;31(9):661-9. doi: 10.1089/jir.2010.0075. Epub 2011 May 25.

PMID:
21612442
7.

Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.

van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W.

Pharm Res. 2011 Oct;28(10):2393-402. doi: 10.1007/s11095-011-0451-4. Epub 2011 May 5.

8.

Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W.

Pharm Res. 2010 Sep;27(9):1812-24. doi: 10.1007/s11095-010-0172-0. Epub 2010 May 25.

9.

Immunological mechanism underlying the immune response to recombinant human protein therapeutics.

Sauerborn M, Brinks V, Jiskoot W, Schellekens H.

Trends Pharmacol Sci. 2010 Feb;31(2):53-9. doi: 10.1016/j.tips.2009.11.001. Epub 2009 Dec 4.

PMID:
19963283
10.

B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins?

Sauerborn M, Schellekens H.

Curr Opin Biotechnol. 2009 Dec;20(6):715-21. doi: 10.1016/j.copbio.2009.10.007. Epub 2009 Nov 4. Review.

PMID:
19892544
11.

Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.

van Beers MM, Sauerborn M, Gilli F, Hermeling S, Brinks V, Schellekens H, Jiskoot W.

J Immunol Methods. 2010 Jan 31;352(1-2):32-7. doi: 10.1016/j.jim.2009.10.005. Epub 2009 Oct 24.

PMID:
19857496
12.

The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified.

Groseth A, Charton JE, Sauerborn M, Feldmann F, Jones SM, Hoenen T, Feldmann H.

Virus Res. 2009 Mar;140(1-2):8-14. doi: 10.1016/j.virusres.2008.10.017. Epub 2008 Dec 16.

13.

Proteolytic processing and oligomerization of bacteriophage-derived endosialidases.

Mühlenhoff M, Stummeyer K, Grove M, Sauerborn M, Gerardy-Schahn R.

J Biol Chem. 2003 Apr 11;278(15):12634-44. Epub 2003 Jan 29.

14.
15.

Insights into carbohydrate recognition by Narcissus pseudonarcissus lectin: the crystal structure at 2 A resolution in complex with alpha1-3 mannobiose.

Sauerborn MK, Wright LM, Reynolds CD, Grossmann JG, Rizkallah PJ.

J Mol Biol. 1999 Jul 2;290(1):185-99.

PMID:
10388566
16.
17.

Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile.

Hundsberger T, Braun V, Weidmann M, Leukel P, Sauerborn M, von Eichel-Streiber C.

Eur J Biochem. 1997 Mar 15;244(3):735-42.

18.

Definition of the single integration site of the pathogenicity locus in Clostridium difficile.

Braun V, Hundsberger T, Leukel P, Sauerborn M, von Eichel-Streiber C.

Gene. 1996 Nov 28;181(1-2):29-38.

PMID:
8973304
19.

Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins.

von Eichel-Streiber C, Boquet P, Sauerborn M, Thelestam M.

Trends Microbiol. 1996 Oct;4(10):375-82. Review.

PMID:
8899962
21.

Comparative sequence analysis of the Clostridium difficile toxins A and B.

von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J, Sauerborn M.

Mol Gen Genet. 1992 May;233(1-2):260-8.

PMID:
1603068
22.

Morphological changes in adherent cells induced by Clostridium difficile toxins.

von Eichel-Streiber C, Warfolomeow I, Knautz D, Sauerborn M, Hadding U.

Biochem Soc Trans. 1991 Nov;19(4):1154-60. No abstract available.

PMID:
1794484
24.

Nucleotide sequence of Clostridium difficile toxin A.

Sauerborn M, von Eichel-Streiber C.

Nucleic Acids Res. 1990 Mar 25;18(6):1629-30. No abstract available.

25.

Cloning of Clostridium difficile toxin B gene and demonstration of high N-terminal homology between toxin A and B.

von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J, Sauerborn M.

Med Microbiol Immunol. 1990;179(5):271-9.

PMID:
2082160

Supplemental Content

Loading ...
Support Center